Reactions 1704, p48 - 2 Jun 2018
Major and minor bleed: 4 case reports
In a study, two men and two women [ages not stated] were
described, of whom, one man developed major bleed during
direct oral anticoagulation (DOAC) therapy with rivaroxaban,
and the remaining three patients developed minor bleed
during DOAC therapy with apixaban.
The patients had been receiving DOAC therapy with
rivaroxaban 15mg once daily (1 patient), apixaban 2.5mg twice
daily (2 patients) and apixaban 5mg twice daily (1 patient).
Subsequently, the patient, who had been receiving
rivaroxaban, developed major bleed (n=1) and the patients,
who had been receiving apixaban, developed minor bleed
(n=3) [times to reaction onsets and outcomes not stated].
Author comment: "Side-effects, listed in table 1, were
common, ([rivaroxaban] 29.3%; [apixaban] 25.4%), although
these were minor and transient in many cases."
Nunn M, et al. Side-effects of doacs in middle-age (56-74 years). British Journal of
Haematology 181 (Suppl. 1): 201-202 abstr. BSH18-EP-085, 16 Apr 2018.
Available from: URL: https://doi.org/10.1111/bjh.15226 [abstract] - United
Reactions 2 Jun 2018 No. 17040114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved